Literature DB >> 15029476

[Prevention of nephrolithiasis. Established strategies and new concepts].

M Straub1, R E Hautmann.   

Abstract

During the last 2 decades in Germany, only minor efforts were expended for the prevention of urinary stones. Substantial technical progress simplified the treatment of existing calculi; thus, it was more convenient to treat a new stone than to prevent its recurrence. But times change! In these days of financial squeeze in the medical system, prevention becomes more attractive. Nevertheless, strategies for kidney stone prevention developed. Established concepts for dietary advice were rejected due to the results of new randomized studies. Moreover, new pharmacological substances were introduced for metaphyalxis. The new concepts are feasible for the daily routine. For some treatment modalities in stone prevention, there is valid evidence from the literature, which should encourage us to adopt these modalities in the future. A number of drugs are used as "good common practice" without any proof from a randomized trial. Often prospective and valid studies are not available. The present paper intends to describe the status quo of nephrolithiasis prevention in Germany, focussing on confirmed data and unsolved problems.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15029476     DOI: 10.1007/s00120-003-0514-1

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  43 in total

1.  [Socioeconomic aspects of urinary calculi and metaphylaxis of urinary calculi].

Authors:  W L Strohmaier
Journal:  Urologe A       Date:  2000-03       Impact factor: 0.639

Review 2.  Drug-induced urolithiasis.

Authors:  C A Osborne; J P Lulich; J W Bartges; L K Ulrich; L A Koehler; K A Bird; L L Swanson; G W Austin; E L Prien; K U Steinam
Journal:  Vet Clin North Am Small Anim Pract       Date:  1999-01       Impact factor: 2.093

3.  [Urolithiasis: the calculus is gone, what now? Principles of urinary calculus metaphylaxis].

Authors:  W Vahlensieck; A Hesse; A Nolde
Journal:  Urologe A       Date:  1993-07       Impact factor: 0.639

4.  Uric acid and calcium oxalate nephrolithiasis.

Authors:  F L Coe
Journal:  Kidney Int       Date:  1983-09       Impact factor: 10.612

5.  Effect of blackcurrant-, cranberry- and plum juice consumption on risk factors associated with kidney stone formation.

Authors:  T Kessler; B Jansen; A Hesse
Journal:  Eur J Clin Nutr       Date:  2002-10       Impact factor: 4.016

6.  Medical treatment of cystinuria: critical reappraisal of long-term results.

Authors:  F Barbey; D Joly; P Rieu; A Méjean; M Daudon; P Jungers
Journal:  J Urol       Date:  2000-05       Impact factor: 7.450

7.  Randomized trial of allopurinol in the prevention of calcium oxalate calculi.

Authors:  B Ettinger; A Tang; J T Citron; B Livermore; T Williams
Journal:  N Engl J Med       Date:  1986-11-27       Impact factor: 91.245

8.  [Cystinuria therapy by ascorbic acid (author's transl)].

Authors:  R Asper; O Schmucki
Journal:  Urol Int       Date:  1982       Impact factor: 2.089

9.  Chlorthalidone reduces calcium oxalate calculous recurrence but magnesium hydroxide does not.

Authors:  B Ettinger; J T Citron; B Livermore; L I Dolman
Journal:  J Urol       Date:  1988-04       Impact factor: 7.450

10.  [Uric acid and oxalate lithiasis. Physico-chemical and crystallo-chemical explanation of the relationship].

Authors:  P Leskovar
Journal:  Z Urol Nephrol       Date:  1980-03
View more
  3 in total

Review 1.  [Urinary calculi. Metabolism and diagnosis].

Authors:  R E Hautmann; M Straub
Journal:  Urologe A       Date:  2006-09       Impact factor: 0.639

2.  [Silica-containing urinary stones--clinical issues to keep in mind].

Authors:  M May; C Helke; K Kubenz; M Seehafer; M Wolter; B Hoschke
Journal:  Urologe A       Date:  2005-01       Impact factor: 0.639

Review 3.  [Urolithiasis in children--rational diagnosis, therapy, and metaphylaxis].

Authors:  D Fahlenkamp; B Noack; S Lebentrau; H Belz
Journal:  Urologe A       Date:  2008-05       Impact factor: 0.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.